에 대한 최신 뉴스 IGM Biosciences (NASDAQ:IGMS) 주식

IGM Biosciences

IGM Biosciences Inc is a biotechnology company engaged in the development of IgM antibody therapeutics for the treatment of cancer, infectious diseases, and autoimmune and inflammatory diseases. Its IgM antibody technology platform is suited for developing T cell engagers, receptor cross-linking agonists, and targeted cytokines. Its product candidate, Aplitabart: An IgM antibody targeting Death Receptor 5 (DR5) proteins, for the treatment of colorectal cancer; Imvotamab: A bispecific for severe systemic lupus erythematosus (SLE) and one for severe rheumatoid arthritis (RA); and IGM-2644: A bispecific T cell engaging IgM antibody targeting CD38 and CD3 proteins, currently planned for evaluation in autoimmune disease.

Russell,2000,Index.magnifying,Glass,Showing,The,Words.background,Of,Banknotes,And

Analyst Color

Broad U.S. Equity ETFs

Small Cap

ETFs

EVGO

IGMS

LNTH

MORF

OUST

PLSE

SOUN

iShares Russell 2000 ETF가 추적하는 러셀(Russell) 2000 소형주 지수는 2023년 10월 이후 최고의 주간 실적을 기록하여 6% 이상 급등하여 2022년 1월 이후 최고 수준에 도달했다.

러셀 2000 지수, 연중 가장 강한 주를 기록하며 31개월 최고치를 기록

IGM Biosciences Inc

Piper Sandler analyst David Amsellem initiates coverage on Bristol-Myers Squibb (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>) with a Overweight rating and announces Price Target of $65.

News

Price Target

Initiation

Analyst Ratings

Piper Sandler Initiates Coverage On Bristol-Myers Squibb with Overweight Rating, Announces Price Target of $65

Barclays analyst Tom O'Malley maintains Qorvo (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QRVO#NASDAQ">QRVO</a>) with a Equal-Weight and lowers the price target from $80 to $60.

QRVO

Barclays Maintains Equal-Weight on Qorvo, Lowers Price Target to $60

Barclays analyst Blayne Curtis maintains NXP Semiconductors (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NXPI#NASDAQ">NXPI</a>) with a Overweight and lowers the price target from $230 to $190.

NXPI

Barclays Maintains Overweight on NXP Semiconductors, Lowers Price Target to $190

Stifel analyst Benjamin Nolan maintains New Fortress Energy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NFE#NASDAQ">NFE</a>) with a Buy and lowers the price target from $16 to $14.

Stifel Maintains Buy on New Fortress Energy, Lowers Price Target to $14

WIIM

Sciencejoy Holding shares are trading higher. The company reported Q4 financial results.

Barclays analyst Blayne Curtis maintains NVIDIA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) with a Overweight and lowers the price target from $175 to $155.

NVDA

Barclays Maintains Overweight on NVIDIA, Lowers Price Target to $155

Stifel analyst Steven Wieczynski maintains Light &amp; Wonder (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LNW#NASDAQ">LNW</a>) with a Hold and lowers the price target from $93 to $84.

Stifel Maintains Hold on Light & Wonder, Lowers Price Target to $84

Stifel analyst Stephen Gengaro maintains Liberty Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LBRT#NYSE">LBRT</a>) with a Buy and lowers the price target from $23 to $22.

LBRT

Stifel Maintains Buy on Liberty Energy, Lowers Price Target to $22

Stifel analyst Jeffrey Stantial maintains Intl Game Tech (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IGT#NYSE">IGT</a>) with a Buy and lowers the price target from $26 to $22.

Stifel Maintains Buy on Intl Game Tech, Lowers Price Target to $22

Scienjoy Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SJ#NASDAQ">SJ</a>) reported quarterly losses of $(0.01) per share. This is a 133.33 percent decrease over earnings of $0.03 per share from the same period last year. The company reported $42.50 million in sales this quarter. This is a 33.85 percent decrease over sales of $64.25 million the same period last year.

Earnings

Scienjoy Holding Q4 2024 Adj EPS $(0.01), Sales $42.50M

Stifel analyst Jeffrey Stantial maintains Flutter Entertainment (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FLUT#NYSE">FLUT</a>) with a Buy and lowers the price target from $320 to $315.

FLUT

Stifel Maintains Buy on Flutter Entertainment, Lowers Price Target to $315

Stifel analyst Jeffrey Stantial maintains DraftKings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DKNG#NASDAQ">DKNG</a>) with a Buy and lowers the price target from $57 to $53.

DKNG

Stifel Maintains Buy on DraftKings, Lowers Price Target to $53

Stifel analyst Benjamin Nolan maintains Cheniere Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LNG#NYSE">LNG</a>) with a Buy and lowers the price target from $255 to $247.

Stifel Maintains Buy on Cheniere Energy, Lowers Price Target to $247

KOPN

Kopin shares are trading higher after the company announced a $7.5 million contract to supply microdisplays for pilot helmet mounted display systems.

MASS

908 Devices shares are trading higher after the company announced it received a $2 million order from the Texas Department of Public Safety for Drug Detection and Mitigation

Stifel analyst Ruben Roy initiates coverage on CoreWeave (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRWV#NASDAQ">CRWV</a>) with a Buy rating and announces Price Target of $55.

CRWV

Stifel Initiates Coverage On CoreWeave with Buy Rating, Announces Price Target of $55

Orla Mining (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/ORLA#AMEX">ORLA</a>) has outperformed the market over the past 5 years by 24.1% on an annualized basis producing an average annual return of 36.96%. Currently, Orla Mining has a market capitalization of $3.70 billion. 
Buying $100 In ORLA: If an investor had bought $100 of ORLA stock 5 years ago, it would be worth $515.25 today based on a price of $11.49 for ORLA at the time of writing.
<h3>Orla Mining's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1745335824_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Trading Ideas

ORLA

Here's How Much $100 Invested In Orla Mining 5 Years Ago Would Be Worth Today

SHOP

Shopify shares are trading higher. Goldman Sachs maintained a Buy rating on the stock.

Barclays analyst Tom O'Malley maintains Micron Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MU#NASDAQ">MU</a>) with a Overweight and lowers the price target from $115 to $95.

Barclays Maintains Overweight on Micron Technology, Lowers Price Target to $95

Alliance Global Partners analyst Aaron Grey initiates coverage on Waldencast (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WALD#NASDAQ">WALD</a>) with a Buy rating and announces Price Target of $5.

WALD

Alliance Global Partners Initiates Coverage On Waldencast with Buy Rating, Announces Price Target of $5

Press Releases

IGM Biosciences Announces First Quarter 2024 Financial Results and Provides Corporate Update

Treatment.com AI Inc. (TRUE.CN) Advances AI in Healthcare with Strategic Moves

Health Care

IGM Biosciences to Present at the Jefferies Healthcare Conference

IGM Biosciences Announces Second Quarter 2024 Financial Results and Provides Corporate Update

IGM Biosciences to Present at the Stifel 2024 Virtual Immunology and Inflammation Summit

IGM Biosciences Announces Strategic Pivot to Focus Exclusively on Autoimmunity

IGM Biosciences to Present at Three Upcoming Investor Conferences

IGM Biosciences Announces Third Quarter 2024 Financial Results and Provides Corporate Update

IGM Biosciences Provides Strategic Update on Autoimmunity Pipeline Programs

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of IGM Biosciences, Inc. - IGMS

AKTS

BNED

CSE:TRUE

GWAV

Achieve Life Sciences, Inc. - Common Shares

Achieve Life Sciences

Adagene Inc. - ADS, each representing 1.25 ordinary shares

Adagene

Assembly Biosciences, Inc. - Common Stock

Assembly Biosciences

Atossa Therapeutics

Aerovate Therapeutics, Inc. - Common Stock

Aerovate Therapeutics

Climb Bio

Corbus Pharmaceuticals Holdings, Inc. - Common Stock

Corbus Pharmaceuticals

Caribou Biosciences

CervoMed

Elicio Therapeutics

Galectin Therapeutics Inc. - Common Stock

Galectin Therapeutics

Genenta Science S.p.A. - American Depositary Shares

Genenta Science

HilleVax

I-MAB

Invivyd

Jasper Therapeutics, Inc. - Class A Common Stock

Jasper Therapeutics

MediciNova

OncoCyte

Sagimet Biosciences Inc. - Series A Common Stock

Sagimet Biosciences

Tenaya Therapeutics

Vigil Neuroscience

Vaxart

Whitehawk Therapeutics, Inc. - Common Stock

Whitehawk Therapeutics

Exicure

Exagen

Jefferies

Truist Securities

Stifel

RBC Capital

BMO Capital

iShares Russell 2000 ETF가 추적하는 러셀(Russell) 2000 소형주 지수는 2023년 10월 이후 최고의 주간 실적을 기록하여 6% 이상 급등하여 <a href="https://www.benzinga.com/topic/small-caps" target="_blank" rel="noopener" data-google-interstitial="false">2022년 1월 이후</a> 최고 수준에 도달했다.
이러한 랠리는 주로 목요일 세션에 의해 주도되었으며, 러셀 2000 지수는 일일 3.6%라는 놀라운 상승률을 기록했다. 이번 급등은 예상보다 낮은 6월 인플레이션 데이터에 따른 것이며, 이로 인해 잠재적인 금리 인하 가능성에 대한 기대가 강화되었다.
그러나 LPL 파이낸셜의 최고 글로벌 전략가인 퀸시 크로스비(Quincy Krosby)는 러셀 2000의 금리 인하 메시지가 &#8220;노동 시장에 대한 연방준비제도(연준)의 우려로 인해 흐려질 수 있다&#8221;고 시사하면서 주의를 조언했다.
크로스비는 노동시장 약화가 경제적으로 민감한 러셀 2000 지수에 여전히 타격을 줄 것이며, 금리 인하가 반드시 더 광범위한 경기 둔화로부터 지수를 보호할 수는 없을 것이라고 생각한다.
<h2 class="wp-block-heading">이번 주의 차트: 8개월 만에 최대 성과를 올린 소형주 지수</h2>
<figure class="wp-block-image size-large"><img loading="lazy" decoding="async" class="wp-image-434094" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/07/12145314/Screenshot-2024-07-12-alle-20.34.21-1024x488.png" sizes="(max-width: 1024px) 100vw, 1024px" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/07/12145314/Screenshot-2024-07-12-alle-20.34.21-1024x488.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/07/12145314/Screenshot-2024-07-12-alle-20.34.21-300x143.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/07/12145314/Screenshot-2024-07-12-alle-20.34.21-768x366.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/07/12145314/Screenshot-2024-07-12-alle-20.34.21-1536x732.png 1536w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/07/12145314/Screenshot-2024-07-12-alle-20.34.21.png 1920w" alt="" width="1024" height="488" /></figure>
출처: <a href="URL http://www.benzinga.com/pro/register/?utm_source=BZprocontent071224&amp;t=be2bearmibe3na1">Benzinga Pro</a>
러셀 2000의 인상적인 성과는 투자자들이 거대 기술 기업들에서 벗어나 더 넓은 시장으로 직접 유입됨에 따라 금리에 민감한 중소형주가 이익을 얻는 등 시장 초점의 상당한 변화를 강조한다고 크로스비가 강조했다.
이 분석가는 러셀 2000이 잠재적인 금리 완화와 광범위한 경제 상황에 대한 중요한 지표 역할을 한다고 지적했다. 일반적으로 중소형주 유니버스는 매력적인 밸류에이션에도 불구하고 심각한 경기 둔화 조짐이 보이면 매도할 것이다.
"역사적으로 러셀 2000은 첫 번째 금리 인하 이후 3개월 동안 시장보다 뒤쳐졌다. 연준이 일반적으로 경제, 특히 노동 시장에 대한 우려로 금리를 인하하기 때문이다. 파월 의장은 연준의 최대 고용 의무화를 계속해서 주장하면서 연준이 경제 지원을 위해 더 빠른 속도로 금리를 인하할 것이라는 점을 분명히 했다"고 그녀가 말했다.
노동 시장 상황이 악화되면 연준은 예정된 9월 18일 회의보다 더 빨리 완화 주기를 시작할 수도 있다고 크로스비는 말했다. 시장에서는 경기 호조 속에서 인플레이션 완화에 따른 금리 인하를 선호하고 있다.
<h2 class="wp-block-heading">이번 주 러셀 2000에서 가장 높은 성과를 기록한 상위 10개 회사 </h2>
<ol>
<li>모픽 홀딩 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MORF#NASDAQ">MORF</a>): 75.16% (헬스케어)</li>
<li>랜티우스 홀딩스 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LNTH#NASDAQ">LNTH</a>): 55.47% (헬스케어)</li>
<li>IGM 바이오사이언스 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IGMS#NASDAQ">IGMS</a>): 54.22% (헬스케어)</li>
<li>사운드하운드 AI (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SOUN#NASDAQ">SOUN</a>): 52.63% (정보기술)</li>
<li>메소드 일렉트로닉스 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MEI#NASDAQ">MEI</a>): 47.96% (정보기술)</li>
<li>솔라리스 오일필드 인프라스트럭처 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SOI#NYSE">SOI</a>): 46.87% (에너지)</li>
<li>펄스 바이오사이언스 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLSE#NASDAQ">PLSE</a>): 45.98% (헬스케어)</li>
<li>아우스터 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OUST#NYSE">OUST</a>): 44.21% (정보기술)</li>
<li>EV고 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EVGO#NASDAQ">EVGO</a>): 42.65% (소비자 자유롭게 선택 가능한 소비재)</li>
<li>선런 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RUN#NASDAQ">RUN</a>): 42.51% (산업재)</li>
</ol>
지금 읽기:
<ul>
<li><a href="https://www.benzinga.com/markets/equities/24/07/39750466/us-consumer-morale-dips-more-than-expected-in-july-sentiment-remains-stubbornly-subdued">미국 소비자 심리, 7월 예상보다 감소&#8230;전망은 &#8216;완고하게 억제된 상태&#8217;</a></li>
</ul>
사진: 셔터스톡
다른 트레이더들보다 30분 일찍 독점 시장 움직임 뉴스를 받아보세요 
Benzinga Pro의 14일 무료 체험을 통해 독점 뉴스 기사를 이용할 수 있어 수백만 명의 다른 트레이더보다 먼저 실행 가능한 거래 뉴스를 얻을 수 있습니다. <a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor" target="_blank" rel="noreferrer noopener">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

Comments

IGM Biosciences

뉴스

에 대한 최신 뉴스 IGM Biosciences (NASDAQ:IGMS) 주식

금요일, 7월 12, 2024

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌